Exact Sciences reported third‑quarter revenues of $850.7 million, a 20% increase year‑over‑year, driven by growth in its Cologuard screening business and rising precision oncology revenues. Screening revenue rose 22% to $666.2 million while precision oncology climbed 13% to $184.5 million. Management raised full‑year guidance and highlighted accelerating test volumes and expanded adoption of its colorectal screening products and nascent blood‑based assays. The results underscore continued commercial momentum in cancer screening markets and support Exact’s strategy to extend the Cologuard brand into new blood‑based tests and MRD applications.